Prevention of venous thromboembolism after major orthopedic surgery: Indirect comparison of three new oral anticoagulants

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 9, 2011, Pages 1868-1870

  Maratea, D ^a   Fadda, V ^a   Trippoli, S ^a   Messori, A ^a  

^a ESTAV   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; ENOXAPARIN; RIVAROXABAN;

ANTICOAGULANT THERAPY; BAYES THEOREM; CLINICAL ASSESSMENT; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; LETTER; LUNG EMBOLISM; ORTHOPEDIC SURGERY; OUTCOME ASSESSMENT; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURGICAL RISK; SYMPTOM; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; ENOXAPARIN; HUMANS; MORPHOLINES; ORTHOPEDIC PROCEDURES; PYRAZOLES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 80052422571     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04421.x     Document Type: Letter

References (18)

1. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002; 21: 2313-24.
2. Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, Lee K, Boersma C, Annemans L, Cappelleri JC. Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. Value Health 2011; 14: 417-28.
3. Fadda V, Maratea D, Trippoli S, Messori A. Network meta-analysis. Results can be summarised in a simple figure. BMJ 2011; 342: d1555.
4. Messori A, Del Santo F, Maratea D. First-line treatments for hepatitis C. Aliment Pharmacol Ther 2011; 33: 1383-5.
5. Messori A, Del Santo F, Maratea D, Trippoli S. Single-drug treatments for chronic hepatitis B: summarising current information on effectiveness by network meta-analysis. Aliment Pharmacol Ther 2011; 34: 105-7.
6. Passaro D, Fadda V, Maratea D, Messori A. Anti-platelet treatments in acute coronary syndrome: simplified network meta-analysis. Int J Cardiol 2011; doi: 10.1016/j.ijcard.2011.05.083.
7. Fadda V, Maratea D, Trippoli S, Messori A. Treatments for macular degeneration: summarising evidence using network meta-analysis. Br J Ophthalmol 2011; doi: 10.1136/bjophthalmol-2011-300316.
8. Brenner B, Hoffman R. Emerging options in the treatment of deep vein thrombosis and pulmonary embolism. Blood Rev 2011; doi: 10.1016/j.blre.2011.04.003.
9. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807-15.
10. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487-98.
11. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-86.
12. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-9. Epub 2008 Jun 24.
13. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-75.
14. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-56.
15. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Büller HR; RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-85.
16. Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ; for the RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011; 105: 721-9. Epub 2011 Jan 12.
17. Canadian Agency for Drugs and Technologies in Health (CADTH). Indirect Treatment Comparison (ITC) software. Accessed 16 June 2011.
18. REVMAN Software. Copenhagen: Cochrane Collaboration, 2008.